LONDON, November 4 /PRNewswire/ --

Planalytics Inc., the global leader in Business Weather Intelligence(R), explained in its October WeatherCall(SM) report that the month was generally typical in terms of breezy and cool conditions. However, inconsistent temperatures and precipitation patterns kept retailers guessing throughout the month. Footwear companies seemed to benefit the most overall, selling items such as boots.

The biggest story of the month was the wintry finale, as snow fell in some parts of England and Wales. This was the first October snowfall in the southeast since 1974 and for central London, since 1934. This caused a large run up in sales for outerwear and cold weather accessories.

WASHINGTON, November 4 /PRNewswire/ --

FairWinds Partners, LLC, has been working with Verizon Communications to develop and implement an innovative approach to optimizing Verizon's domain portfolio. This new approach has enabled Verizon not only to better provide its customers with more relevant online experiences that deliver desired content, but also to do so in a more cost-effective manner.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070810/NEF018 )

CALGARY, Canada, November 4 /PRNewswire/ -- Oncolytics Biotech Inc. (Oncolytics) (TSX:ONC, NASDAQ:ONCY) announced today that it has made a decision to pursue a pivotal (Phase II/III) randomized trial using the combination of REOLYSIN(R) with paclitaxel/carboplatin in refractory patients with head and neck cancers. The decision was made following a review of results by the Company's Board of Directors from the Company's ongoing U.K. Phase I and Phase II combination REOLYSIN(R) and paclitaxel/carboplatin clinical trials. The results were presented November 1, 2008 at the International Society for Biological Therapy of Cancer (iSBTc) annual meeting in San Diego, CA.

TORONTO and CHARLOTTETOWN, Canada, November 4 /PRNewswire/ --

- Canadian Companies Team up in Specialty Biologics Development

TORONTO and CHARLOTTETOWN, Canada, November 4 /PRNewswire/ --

BioVectra Inc. and Therapure BioPharma Inc. have agreed to partner in the development of a PEGylated biologic drug target used for cancer treatments, with a goal of advancing the project to a regulatory filing stage, suitable for a marketing partner to add to its portfolio of biologic products.

CAIRO, November 4 /PRNewswire/ --

- eOffice Amongst Those Applying Early in First Come, First Served Process

With one month to go until Sunrise opens, trademark owners were today warned that they risk missing out on being listed in the new global, 'live' contacts directory if they fail take advantage of the first come, first served application period for their branded .tel domains.